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Abstract
Background: Despite high potential for HIV-1 genetic variation, the emergence of some mutations is constrained by fitness
costs, and may be associated with compensatory amino acid (AA) co-variation. To characterize the interplay between
Cytotoxic T Lymphocyte (CTL)-mediated pressure and HIV-1 evolutionary pathways, we investigated AA co-variation in Gag
sequences obtained from 449 South African individuals chronically infected with HIV-1 subtype C.
Methodology/Principal Findings: Individuals with CTL responses biased toward Gag presented lower viral loads than
individuals with under-represented Gag-specific CTL responses. Using methods that account for founder effects and HLA
linkage disequilibrium, we identified 35 AA sites under Human Leukocyte Antigen (HLA)-restricted CTL selection pressure
and 534 AA-to-AA interactions. Analysis of two-dimensional distances between co-varying residues revealed local
stabilization mechanisms since 40% of associations involved neighboring residues. Key features of our co-variation analysis
included sites with a high number of co-varying partners, such as HLA-associated sites, which had on average 55% more
connections than other co-varying sites.
Conclusions/Significance: Clusters of co-varying AA around HLA-associated sites (especially at typically conserved sites)
suggested that cooperative interactions act to preserve the local structural stability and protein function when CTL escape
mutations occur. These results expose HLA-imprinted HIV-1 polymorphisms and their interlinked mutational paths in Gag
that are likely due to opposite selective pressures from host CTL-mediated responses and viral fitness constraints.
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Introduction
HIV is characterized by extensive genetic diversity, yet
significant segments of the HIV-1 proteome are conserved across
all subtypes [1], implying that there are limits to HIV variability:
not all codons have been found to accept a mutation, and some
replacements are only found in the presence of other mutations,
exemplifying an evolutionary co-variation process among these
amino acids (AA).
To assess co-variation robustly, Poon [2] and Carlson and their
colleagues [3,4,5] developed phylogenetically-informed methods,
which were designed to remove spurious associations stemming
from shared ancestry and HLA linkage. A central tenet for
assessing co-variation is the covarion principle, proposed by Fitch
and Markowitz in 1970 [6], which states that ‘at any one point in
time only a very restricted number of positions can fix mutations
but that as mutations are fixed, the positions capable of accepting
mutations also change so that examination of a wide-range of
species reveals a wide range of altered positions. We define this
restricted group as the concomitantly variable codons [and]
suggest the term ‘‘covarions’’ to describe this particular set of
codons.’
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12463Experimentally, it has been shown that AA changes are often
coupled: Yanofsky and colleagues first showed in 1964 that second-
site compensatorymutationscouldsuppressthe deleteriouseffectsof
some mutations [7]. Since then, several genetic studies have
revealed cooperative AA changes, including, for HIV patients on
antiretroviral therapy, the development in Pol of drug resistance
mutations (DRM) which were accompanied by the fixation of
secondary mutations [8–15]. Examples of compensatory changes in
HIV-1 Gag include the partial restoration of the fitness cost of the
CTL escape mutation A163G (in the B*5703 KAFSPEVIPMF) by
the S165N change within the epitope [16]; likewise, the fitness cost
of the CTL escape mutation R264K (in the B*27 KRWIILGLNK)
is partially restored by S173A [17], and the I147L in QAISPRTL-
NAW (QW11) mutation partially compensates the fitness cost
associated with the escape mutation A146P [18].
To better understand the structural variability of HIV-1, and
specifically the relationship between interlinked mutations and
compensatory changes, we assessed patterns of co-variation in subtype
C Gag in a cohort of chronically infected persons who had not received
antiretroviral treatment at the time of analysis. Gag-specific CTL
responses are considered important in the control of HIV replication
[19], and certain Gag CTL escape mutations reduce viral fitness,
thereby possibly promoting the containment of a partially-crippled
virus [1,16,17,20,21]. Our study sought to build upon studies
describing HLA-driven HIV-1 variation using phylogenetic correction
[22,23] by further analyzing co-variation pathways that have partially
been described [4] in order to link these CTL escape mutations.
Results
Protective effect of CTL responses targeting conserved
HIV-1 proteins, specifically Gag
Our study focused on a previously described dataset [19,24] that
included viral genomic sequences, CTL response mapping, HLA-
types and clinical data from 598 treatment naı ¨ve, chronically infected
individuals from KwaZulu-Natal in South Africa; ,99% of them
were infected with HIV-1 subtype C. To initially assess the
relationship between responses to viral proteins and viral loads, we
calculated a ‘‘protective ratio’’ for each protein. This corresponded to
the Log10 of the viral load of the individuals who had no CTL
response against a protein, and the average viral load of the
individuals who had at least one CTL response against that protein
(Log10(VL non-responders/VL responders)). A positive protective
ratio indicated that individuals recognizing the protein had lower
viral loads than individuals who did not recognize the protein.
Positive protective ratios were detected when having a CTL response
against Gag and to a lesser extent Pol, Vpr and Vpu (Figure 1, x axis).
In contrast, individuals mounting at least one response against other
proteins, especially Vif, Env and Tat but also Rev and Nef, had
higher viral loads than those who did not recognize those proteins
(negative protective ratios). By comparing the protective ratios to the
mean entropy values of each protein, we found a negative
relationship, indicating that the most protective protein-specific
CTLresponses(withlowerlevelsofviremia)correspondedtoproteins
of lower entropy: Spearman’s correlation coefficient Rho
r=20.7167, p=0.0298 (r
2=0.5021, p=0.0326) (Figure 1). In light
of the beneficial role of Gag-specific CTL responses, we then
characterized patterns of genetic variation in Gag sequences,
particularly those linked to HLA-mediated mutations.
Identification of co-varying residues in HIV-1 subtype C
Gag
We determined AA interactions in Gag HIV-1 subtype C based
on sequences and HLA type data obtained from 449 chronically-
infected individuals. To correct for founder effects and HLA
linkage disequilibrium, we identified associations using the
program PhyloD [4], which we ran on 5 trees selected from a
set of trees for their high log likelihood scores. Selecting the
associations that met our congruence criteria (stable in the 5 tree
topologies and q,0.1) resulted in a set of 727 associations: 69 (of
the initial 74) HLA-restricted AA associations and 658 (of the
initial 831) AA-to-AA associations. When symmetrical/reciprocal
associations involving the same sites in the alignment were counted
only once, we obtained 534 unique site-specific associations, which
are displayed via connected arcs in a circle map (Figure 2).
Compared to the distribution of AA in Gag, some AA were over-
or under-represented among co-varying associations. Both lysine
and threonine residues were found twice as often in AA-
associations than expected from the AA distribution in Gag
(two-tailed Fisher’s exact test p=0.006 and 0.030, respectively). In
contrast, glycine and tryptophan were under-represented among
co-varying residues (two-tailed Fisher’s exact test p=0.003 and
0.030, respectively). It could be logical that glycine and
tryptophane were rarely detected among co-varying pairs, since
they are less likely to be replaced by another AA given that they
are the smallest and largest AA, respectively. Thirty-five of the co-
varying sites were HLA-associated, including 30 sites located in
p17/p24, 19 of which had been reported in a previous study of
HLA-imprinted polymorphisms in p17/p24 [22]. HLA-mediated
associations were evenly distributed in p17 and p24: 17 HLA-
associations were identified in p17 and 26 in p24 (two-tailed
Fisher’s exact test p=0.6134).
In this South African cohort, several alleles have been associated
with lower viral loads in infected individuals (B13, B*3910,
B*4201, B57, B*5801, B*8101), we therefore evaluated how these
protective alleles were represented in our analysis. We found that a
majority of HLA-associations were HLA class I B allele
associations (54%) and half of these corresponded to known
protective alleles. Although there was no difference in the
distribution of associations between p17 (n=3) and p24 (n=10)
(two-tailed Fisher’s exact test p=0.55) if we took into account the
respective lengths of p17 and p24, the larger number of HLA-
Figure 1. Relationship between CTL targeting and viremia.
Protein-specific protective ratios were plotted as a function of the mean
entropy of each HIV-1 protein. Protective ratios were calculated as the
Log10 of the viral load of all the individuals who did not mount a CTL
response against a protein over the viral load of all the individuals who
had one or more CTL response(s) directed against that protein.
doi:10.1371/journal.pone.0012463.g001
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control of viral replication ascribed to p24-specific CTL responses.
Distances among co-varying AA residues
A noticeable feature in the network of AA dependencies was the
abundance of ‘neighboring’ interactions (Figure 2). Interactions
between adjacent AA represented 40% of all unique associations,
and those between residues that were no more than 3 AA apart
represented 60% of all associations. Neighboring associations were
significantly more frequent than expected by chance: p-
value=2.23e227 for adjacent residues and p=3.57e258 for
residues no more than 3 residues apart (based on random sampling
of 10,000 associations and two-tailed Fisher’s exact test) (Figure 3).
Likewise, tri-dimensional distances (relative to a trimeric crystal
structure of p17, and NMR structures for p24 and the p17/p24
polyprotein) showed a preponderance of short-range associations:
residues separated by less than 5 Angstro ¨ms (A ˚) corresponded to
27% of the associations in the trimeric crystal structure of p17 and
38% and 30% of the associations on the NMR structures of p24
and p17/p24, respectively. As the number of associations
decreased with increasing physical distance, the significance (q-
value) of the associations also decreased (Pearson’s non-parametric
ranked Rho r=0.332, p,0.0001). Although interactions could be
found up to 464 AA apart in the alignment, the median/mean
linear distances between residues were 79 and 24 AA, respectively.
In 3D structures, the median distance (of the minimum across all 3
structures) was 9 A ˚ and mean distances were 10.2 A ˚ in p24, 10.9 A ˚
in p17 and 11.6 A ˚ in the p17/p24 complex structure. Not
surprisingly, there was a strong correlation between the 2D and
3D distances (Pearson’s Rho r=0.727, p,0.0001) (Figure 3).
Figure 2. Amino Acid associations in HIV-1 subtype C Gag. Associations are depicted with a circular map: AA interactions among residues
are represented with arcs, which are color-coded with a white to purple gradient – white corresponding to the strongest associations (i.e., lower
q-values). HLA-restricted sites are identified by the HLA allele designations around the circle.
doi:10.1371/journal.pone.0012463.g002
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78% (195/251) of p17-associations involved residues both found in
p17, likewise 77% (219/284) of p24-associations were amongst
p24 residues. The number of intra-protein associations was
significantly greater than the number of inter-protein associations,
with p=1.01e210 for p17 and p=2.33e211 for p24 (Fisher’s
exact test). This shows that a majority of interactions were
circumscribed within either p24 or p17, and conversely that a
small number of associations might reflect physical interactions
between the 2 proteins. To support that the associations between
p17–p24 were not false positives, we found that: 1) there was no
correlation between 2D and 3D distances for inter-protein
associations (r=0.2), while there was a positive relationship for
intra- protein associations (r=0.7 for both p17 and p24); 2) 3D
distances for inter-p17-p24 associations were not larger than
would be expected based on intra-p17 or intra-p24 associations
(when correcting for larger 2D distances).
Hubness in Gag subtype C
Another salient feature of the circle network of Gag dependen-
cies is that only a fraction of residues were co-varying: all AA
interactions were confined to 183 sites, whereas 309 ‘orphan’ sites
were never involved in AA associations. An average of 5.4 residues
were found at co-varying sites as opposed to 2.2 AA at orphan sites
(p,0.0001), and the mean Shannon Entropy for co-varying sites
was 0.594 as opposed to 0.168 for orphan sites (p,0.0001).
Interestingly, sites that were both co-varying and HLA-restricted
presented higher average Shannon Entropy (0.725) than other co-
varying sites (0.565) (p=0.036). Signals of co-variation and of
adaptive evolution, as measured by dN/dS deviations, were
detected simultaneously at certain sites: 39% of the co-varying sites
(n=49) had dN/dS .1, i.e., were under positive selection, while
only 1 of the 260 orphan sites was under positive selection
(p,0.0001, Two-Tail Fisher’s exact test). More importantly,
among co-varying sites under selection based on dN/dS, those
that were also HLA-associated were more likely to be under
positive selection (15/23) than those that were not HLA-associated
(34/106) (p=0.004, Two-Tail Fisher’s exact test).
A third noticeable characteristic of the circle map of AA
dependencies is the higher density of associations in specific
segments of Gag: a few sites, called hubs, have large numbers of
connections, while most sites have 1–2 connections (Figure 4). For
the co-varying sites (n=183), the mean number of associations or
hubness (H) was 7.1 (median=5) (values correspond to all AA-to-
AA associations only (not HLA-to-AA) to avoid the confounding
effect of counting HLA-mediated pressure). Of the 35 HLA-
associated sites, 30 of them had at least 5 interactions (maximum
of 40). Hubness values were higher for co-varying HLA-associated
sites (HHLA=9.9) than for co-varying but not HLA-associated sites
(Hnon-HLA=6.4) (p=0.0029). Thus, the fact that HLA-associated
sites were more often co-varying, under positive selection (dN/dS
.1), and had more AA connections suggests that HLA-mediated
selection pressure may drive a substantial proportion of AA co-
variation.
Mutational pathways linked to variable sites
Variable sites can be differentiated by the representation of each
AA at the site. An extreme example was the highly polymorphic
Figure 3. Distances between co-varying residues. The larger graph shows the distribution of the 2D distances between all the pairs of co-
varying AA in Gag. The inset represents the relationship between the 2D and 3D distances.
doi:10.1371/journal.pone.0012463.g003
Gag HIV-1-C Co-Variation
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12463site 28, which was under HLA A*03-mediated selection pressure
(corresponding to the H28R mutation) and at which 10 AA states
and 29 associations were found, revealing a sub-network of
topologically close associations. Two A*03-restricted ‘best-defined’
epitopes span site 28 (RLRPGGKKH, RLRPGGKKHY), and
mutations at position 28 (to residues R/Q/T) were shown to
confer escape from A*03-restricted CTL responses [25].
Another scenario of Gag co-variation at variable sites
corresponded to ‘toggle’ sites at which the two most common
AA were found at relatively equal frequencies. One notable toggle
case was position 357 in the HLA-B*07-restricted epitope GP(G/
S)HKARVL, in which G (unadapted or ancestral AA) and S
(adapted or escape form) were found in 51% and 49% of
sequences, respectively, and individuals having either form
presented comparable viral loads (Median: 47,800 (G) vs 35,850
(S) viral copies). The G357S mutation was associated with the
A370T mutation (q-value=2.93E213).
Last, the most common pattern of AA representation at
variable/co-varying sites corresponded to one AA being present
in the majority of sequences, for example at position 146: A was
present in 75% of the sequences examined, while P was found in
17% of sequences. The A146P mutation has been linked to the C-
terminal B*57-restricted epitope ISPRTLNAW. Position 146, 147
and 149 were co-varying and the A146P mutation was linked to
I147L. Interestingly, Draenert and colleagues [26] showed that
A146P was an epitope processing mutation, and they noted that
‘‘it was unclear why the adjacent intra-epitopic mutation I147L
was associated with HLA-B*57 expression while phylogenetic
analysis had failed to demonstrate positive selection at this site’’.
Here, we showed that A146 was in repulsion with I147 (q=0.005),
and that B*57 was in attraction with P146 (q=1.47E207) and
L147 (q=0.007). This demonstrated that the AA pairs at positions
146 and 147 were co-varying and that there was indeed a B*57-
association with position 147. As further evidence of the co-
dependence of 147L and A146P, Troyer and colleagues [18]
recently showed that A146P can considerably reduce viral
replicative fitness, a cost that can be partially restored by I147L.
Mutational pathways linked to sites under constraints
To utilize co-variation analyses to identify sequence constraints
that could be exploited in a vaccine, we focused on the 66
associations linking conserved sites (i.e., sites where the consensus
AA is present in over 85% of sequences), and analyzed the viral
loads of the individuals with HIV-1 sequences that contained 1)
the consensus residues at both co-varying sites, 2) a rare residue at
both co-varying sites, or 3) only one site presented a consensus
residue. Only a few sites showed significantly lower viral loads for
individuals who presented rare residues at interacting conserved
sites (Table 1), nonetheless, the trend toward lower viral loads may
suggest that the presence of rare residues resulted in viruses with
Figure 4. Hubness across HIV-1 Subtype C Gag. The number of co-varying partners and the Shannon Entropy are represented for each site
along the Gag protein. The blue (lower) part of the bars represent the number of AA-to-AA associations and the red (upper) part of the bars represent
the number of HLA-to-AA associations at each site. The secondary axis refers to the Shannon Entropy at each site in Gag (continuous black line).
doi:10.1371/journal.pone.0012463.g004
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(between conserved sites) involved a total of 73 AA sites, of which
14 were HLA-associated; in comparison, there were 35 HLA-
associated sites for the whole alignment of 492 sites, showing that
associations between conserved sites were more likely to
correspond to HLA-imprinted sites (Fisher’s exact test 2-tail p-
value=0.0051), suggesting that some CTL-mediated escape
mutations are deleterious. Therefore, associations between con-
Table 1. Relationship between viral loads and co-varying associations linking conserved sites.
n
a Median VL % Decrease Wilcoxon p-values
Associations CC
b RR
c CR
d CC RR CR CC v. RR CC v. CR CC v. RR CC v. CR
12K-20R 314 61 37,500 55,100 47 0.749
20R-68L 323 8 44 37,800 52,100 67,650 38 79 0.778 0.565
31L-118A 289 77 38,300 34,800 29 0.992
35V-39R 336 8 31 41,935 62,150 19,300 48 254 0.745 0.01
42E-75L 341 2 32 39,600 1,593 32,350 296 218 0.033 0.231
50L-82V 351 2 23 42,300 20,800 7,050 251 283 0.468 0.006
60I-82V 347 5 25 45,200 4,830 17,300 289 262 0.016 0.038
82V-84T 329 10 37 40,000 5,210 36,100 287 210 0.011 0.978
149P-159I 343 3 28 37,900 271,000 44,350 615 17 0.67 0.787
159I-385G 332 1 41 37,500 157,000 47,800 319 27 0.368 0.87
55E-163A 302 11 61 37,850 18,700 42,300 251 12 0.871 0.667
163A-165S 336 25 13 38,250 56,400 13,500 47 265 0.65 0.201
163A-191V 337 5 32 37,900 56,900 39,750 50 5 0.978 0.873
163A-168V 311 63 38,300 37,200 23 0.982
163A-182Q 307 1 66 37,900 67,500 46,800 78 23 0.77 0.978
163A-242T 303 14 57 42,100 42,300 26,000 0 238 0.731 0.052
163A-267I 338 2 34 37,850 69,300 46,800 83 24 0.678 0.672
20R-165S 314 9 51 37,900 13,500 47,800 264 26 0.676 0.944
177E-186T 347 8 19 40,900 51,300 13,700 25 267 0.548 0.029
182Q-186T 319 5 50 38,300 9,470 49,550 275 29 0.041 0.535
182Q-267I 337 3 34 37,900 51,300 65,850 35 74 0.768 0.911
116Q-186T 337 3 31 40,000 107,000 24,200 168 240 0.248 0.185
165S-186T 324 5 45 41,335 13,700 25,700 267 238 0.504 0.102
173T-186T 337 8 29 40,000 85,650 11,300 114 272 0.704 0.031
186T-190T 346 10 18 40,885 42,450 16,700 4 259 0.407 0.029
186T-384K 335 3 33 42,100 37,800 22,700 210 246 0.873 0.136
218V-219H 313 8 53 37,900 179,500 35,080 374 27 0.028 0.505
219H-332T 286 88 38,100 38,000 0 0.207
219H-247I 305 6 63 37,900 71,540 47,800 89 26 0.238 0.166
247I-250M 322 8 44 37,450 255,000 37,550 581 0 0.009 0.885
247I-255P 341 4 29 37,900 128,000 47,800 238 26 0.3 0.084
224A-225P 351 10 13 37,100 140,500 111,000 279 199 0.038 0.61
285I-303T 316 3 52 38,950 45,000 27,400 16 230 0.892 0.505
303T-323V 291 80 37,900 47,050 24 0.995
303T-377M 281 12 78 40,000 52,150 23,250 30 242 0.839 0.064
303T-310T 313 5 53 39,600 13,200 45,000 267 14 0.33 0.596
331K-332T 324 2 45 36,350 8,720 59,200 276 63 0.203 0.133
118A-332T 300 7 61 39,150 47,800 33,800 22 214 0.432 0.621
127K-332T 302 5 64 37,900 47,800 37,500 26 21 0.966 0.519
332T-336A 311 23 40 38,200 99,000 30,050 159 221 0.122 0.399
Shown are associations that involved an HLA-associated site (in bold) or at which a mutation had a significant impact on viral loads.
aNumber of individuals.
bConsensus AA at both co-varying sites.
cRare residues at both co-varying sites.
dConsensus AA at one site and a rare AA at the other co-varying site.
doi:10.1371/journal.pone.0012463.t001
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to their dependent fitness cost.
For example, in the B*57-restricted epitope KAFSPEVIPMF,
the A163G CTL escape mutation incurs a fitness cost in vitro (A is
found in 89% of sequences), a cost that could partially be restored
by the S165N compensatory mutation [16]. The 4th strongest
association (q-value=2.03e220) in our analysis showed that the
presence of G163 (found in 8% of sequences) was associated with
the S165N mutation (found in 9% of sequences), demonstrating
that our method identifies associations between deleterious and
compensatory mutations. In addition, individuals who had one
rare residue had lower viral loads than individuals with consensus
residues at both sites, while individuals with both rare residues, i.e.,
with the escape and the compensatory residue, had higher viral
loads than individuals with consensus residues at both sites
(Table 1).
HLA-B*81 was associated with polymorphisms at positions 177
(E found in 97% of sequences), 182 (Q in 88%) and 186 (T in
91%); both residues 182 and 186 are embedded in the epitope
TPQDLNTML (B*8101) (Figure 5). There was a positive
relationship between the consensus residues T186 and E177,
while there was a negative relationship between T186 and the
adapted E177D (q-value=2.8e206). Figure 5 shows three p24
chains of HIV-1 subtype C and highlights the epitope
TPQDLNTML and particularly the residues E177, Q182 and
T186: while Q182 and T186 align with each other and are located
on the same face of the helix, E177 appears to interact with the
residue Q182 of the neighboring chain. Interestingly, individuals
presenting viruses with rare residues at one position (177 or 186)
had significantly lower viral loads than those who possessed the
consensus T186 and E177 (Median VL Consensus+Consen-
sus=40,900, Median VL Consensus+Rare=13,700; p=0.029).
The decreased viral loads in the presence of a rare residue hints at
a fitness cost, an hypothesis supported by the reduction in
infectivity (of ,29-fold) reported by von Schwedler and colleagues
with the E177A mutation [27]. Moreover, we performed in vitro
fitness competition assays between viruses with the consensus or
the mutant residue and found that: mutations to a rare residue at
sites 177 and 186 both had a significant fitness cost, a cost that was
amplified when residues were mutated simultaneously (Figure 6).
In addition, we found negative associations between the adapted
AA at positions 182 and 186; in agreement, individuals presenting
viruses with rare residues at both positions 182 and 186 had
significantly lower viral loads than those who possessed consensus
residues (Median VL Consensus+Consensus=38,300, Median VL
Rare+Rare=9,470; p=0.041), suggesting that both escape
mutations may not occur simultaneously except in debilitated
viruses.
Discussion
Our results showed that CTL responses against Gag (as opposed
to responses against other proteins) were fundamental to the
control of viral replication in a cohort of HIV-1 subtype C infected
individuals in KwaZulu-Natal, South Africa, and also suggested
that control of viremia was associated with the reduced variability
of the Gag protein. Analysis of co-variation in HIV-1 Gag subtype
C showed intricate patterns of dependent mutations associated
with CTL-driven polymorphisms.
Our co-variation results were derived with a method that can
overcome traditional challenges for co-variation studies. In
particular, it sets apart co-variation due to selection pressure from
co-variation due to shared ancestry by modeling multiple
interactions simultaneously. Moreover, it is conditioned on the
HLA types observed in each subject, allowing us to identify
pathways of particular interest to CTL escape. Nonetheless, there
are limitations to the identification of co-variation. For example,
associations between two AA that are in different epitopes
restricted by the same HLA allele may be a consequence of
immunodominance patterns, i.e., the preferential or time-ordered
targeting of epitopes. A second issue is the noise in the data; yet,
we note that the fuzziness of the network is inherent to the fast
pace of HIV evolution and the cross-sectional nature of our
Figure 5. Sub-network associated with the HLA-B*81 epitope
TPQDLNTML. The tridimensional structure shows three p24 chains of
HIV-1 subtype C (colored in light blue, golden yellow and pink) and the
epitope TPQDLNTML is highlighted in bright blue on chain A. Side-
chain atoms for the residues E177, Q182 and T186 are represented in
sphere format.
doi:10.1371/journal.pone.0012463.g005
Figure 6. Fitness competition assays between viruses mutated
at residues in the sub-network associated with the HLA-B*81
epitope TPQDLNTML. The relative fitness of viruses presenting a
mutation at site 177, 186 or at both sites is compared to that of the wt
COT virus. Fitness competition assays were performed against a wt COT
virus; the proportion of viral RNA from the mutant and wt viruses was
measured at day zero, three and five (see methods).
doi:10.1371/journal.pone.0012463.g006
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permanent and transient interactions.
The circle map of dependencies illustrated the topological
clustering of AA interactions in Gag, underlining the preponder-
ance of ‘neighboring’ interactions. The distance between co-
varying residues suggests two types of interactions: i) structural
interactions with combined replacements between spatially
proximal AA to maintain the local structure stability, and ii)
functional interactions between pairs of distal AA to connect
distant functional determinants.
It has been shown in protein-protein interaction studies that
essential genes have on average more partners, i.e., higher hubness
[28]. By analogy, one might expect that hubs in Gag might have a
greater impact on viral fitness, since a disturbance at a highly
connected residue would probably be more detrimental to the
virus than a change at a lowly connected site. Accordingly, we
found that HLA-associated sites had conspicuously high numbers
of associations and some CTL escape mutations at those HLA-
restricted sites are known to have a fitness cost [16,18,21,
29,30,31]. By co-analyzing HLA-imprinting and AA-to-AA
interactions in Gag, we described examples of evolutionary
constraints that are forced upon some residues and elucidated
some mutational pathways associated with HLA-restricted poly-
morphisms, for example, linked to the B*57-restricted epitopes
KF11 and IW10.
A key outcome of our analysis is our ability to stratify the
dispensability of particular sites, based on their dependent
mutational pathways, and thereby to better understand the
relationship between AA mutability and viral fitness. Hence, our
CTL-driven mutational dynamics maps reflect the lethality profile
of the protein, and we have found some relationships between the
presence of rare residues at co-varying sites and lower viral loads
for the infected individuals. This pertains to recent vaccine
strategies that have proposed to focus on conserved elements of
HIV-1 [1,32]. The sites that remain conserved despite the
influence of selective forces are of specific interest because they
correspond to the ‘Achille’s heel’ of the virus and are attractive
anti-viral or vaccine targets. We previously proposed a CTL-based
‘Conserved Element’ (CE)-vaccine that would be composed of
conserved elements of the HIV-1 proteome [1,32], based on the
rationale that ‘an efficacious vaccine must elicit responses toward
HIV-1 segments that cannot mutate without severely compromis-
ing viral viability, and must not elicit responses against variable,
immunodominant decoys’. Here, we present a strategy to expand
‘conserved elements’ while still blocking CTL escape paths by
taking into account CTL-driven mutational pathways. Combining
results from replicative fitness competition assays and from
analyses of the effect of mutations on viremia to co-variation data
provides ways to extend CE beyond their minimal length (which is
a consequence of their rigid degree of conservation). For example,
the vaccine insert could include one or both residues of a co-
varying interaction in order i) to link residues that are known to
incur a high fitness cost when mutated or ii) to avoid including
pairs of residues that can compensate the fitness cost associated
with a mutation. In addition, certain HLA-associated hubs under
constraints with multiple connections underline sites that may
represent vulnerable spots for HIV and that can be incorporated
in a vaccine construct.
Materials and Methods
Cohort and data
Study participants were antiretroviral drug naı ¨ve adults from
Durban, KwaZulu-Natal, South Africa. Several studies on this
cross-sectional cohort have been published [16,19,22]; Host (Viral
Loads, CD4 counts, HLA types, ELISpot mapping of CTL
responses) and viral genetic details are also available at: http://
www.hiv.lanl.gov/content/immunology/hlatem/index.html.
Near full-length genomes were PCR-amplified, cloned and
sequenced from plasma-derived RNA samples for 272 individuals
[22,33]. Targeted sequencing of the Gag gene for other study
participants was performed likewise (n=36) [22] or by population
sequencing as previously described (n=141) [16,34,35].
Phylogenetic Analysis
We included one HIV-1 sequence per individual and excluded
sequences that were non-subtype C, inter-subtype recombinants or
hypermutated, based on inspection of alignments and phylogenetic
trees and analysis of pairwise distances among sequences in the
dataset. Recombination was evaluated based on Rousseau et al.
[24], a study that included a subset of the present dataset. The
resulting dataset included 449 HIV-1 Gag subtype C sequences, to
which 12 non-subtype C reference sequences from the Los Alamos
HIV Sequence Database (LANL) were added as an outgroup to
root the trees. Nucleotide sequences were aligned with ClustalW
version 1.8 [36] and manually edited with MacClade v4.08 [37],
resulting in a 1476-nucleotide (nt)-long alignment after stripping
‘gap’ columns that resulted from insertions found in a single
individual. PAUP* [38] was used to generate 500 parsimony trees.
These were used as input in PhyML [39] to reconstruct a set of
maximum likelihood trees by estimating and implementing the
GTR + I + G nucleotide substitution model. We selected 5 trees
with the highest log likelihood scores for subsequent determination
of AA associations.
Identification of AA-to-AA and HLA class I to AA
associations
Co-variation analyses were performed using a recent imple-
mentation of the method of Carlson et al. [4]. This approach fits a
Phylogenetic Dependency Network (PDN) to the data. Each node
in the network represents a binary variable corresponding either to
a specific residue at a given AA site or the presence or absence of
an HLA allele. For each target AA node, the algorithm identifies
the set of other AA and HLA nodes that significantly predicts the
state of the target node, with the resulting probability distribution
conditioned on the phylogeny. For each pair of nodes that are
associated, there are four possible statistical relationships:
attraction is defined as the association of the presence of a
particular predictor variable (AA or HLA allele) with the presence
of a target variable (AA or HLA allele). Conversely, repulsion is
defined as the association of the presence of a predictor variable
and the absence of a target variable. Escape is defined as the
association of the absence of a predictor variable and the absence
of a target variable, while reversion is defined as the absence of a
predictor variable and the presence of a target variable. The
significance of each association is quantified using a likelihood
ratio test, calibrated for multiple testing using q-values [40]. Co-
variation analyses performed independently on the 5 ‘best’ trees
yielded a total of 905 significant associations (q,0.1, correspond-
ing to a false discovery rate of 10%), ranging from 794 (tree 4) to
827 (tree 3) associations per tree. We selected for analysis only the
727 associations that were concordant across all of the tree
topologies.
Characterization of the set of associations
Distances between interacting residues were calculated based on
available tri-dimensional Gag structures, with 3 types of
Gag HIV-1-C Co-Variation
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complex. Since p17 is a trimeric structure, distance measures
between residues may correspond to residues that are on different
molecules in the trimer. Additionally, p17 data was derived from a
crystal structure, thus distances tend to be higher than for the p24
and p17p24 structures, that were obtained by NMR and thereby
include the hydrogen atoms. Reported are the minimum distances
found over the 20+ models.
Shannon entropy scores were calculated with the Entropy1 pro-
gram (www.hiv-web.lanl.gov/content/hiv-db/ENTROPY/entropy.
html).
Detection of Selection
Rates of nonsynonymous (dN) and synonymous (dS) mutational
changes across codon sites were estimated using the Single
Likelihood Ancestor Count (SLAC) [41] approach under the
GTR nucleotide substitution model with a significance level
threshold of 0.05, as implemented in Hyphy [41] (www.hyphy.org).
Fitness competition assays
Viruses. The HIV-1 Subtype B Center of Tree (COT) Gag-
p24 sequence was placed in an NL4-3 backbone using the
restriction sites BstEII and SfiI, which were generated in a Gag-
p24 COT expression plasmid and a pNL4-3 infectious clone. Point
mutations were engineered using the QuikChange XL site-directed
mutagenesis kit (Stratagene). The complete HIV-1 coding region of
the variant viruses were PCR-amplified and sequenced.
Cells, titration of chimeric viruses. CEMx174 cells were
cultured in appropriate medium supplemented with 10% fetal
bovine serum. Viral stocks were generated by transfection of
HEK293T cells with 1 mg of plasmid DNA using Fugene (Roche).
Supernatants were harvested 48 h after transfection, and frozen
aliquots were stored at 280uC. Titers were determined in
CEMx174 cells using the method of Reed and Muench. The
capsid concentration of the viral stocks was quantified by p24
enzyme-linked immunosorbent assay (ELISA).
Viral replication assays. CEMx174 cells were infected with
wt or variant viruses or both; mono- and dual-infections were done
in triplicate. Viruses were added at an MOI=0.005 to 10
5 cells,
and washed 24 hr post-infection. Viral production was monitored
with p24 ELISA and aliquots of supernatants were sampled for 6
days. Viral RNA was extracted from supernatant aliquots, cDNA
synthesis was done using SuperScriptIII (Invitrogen) and genes of
interest were amplified by PCR and fully sequenced to quantitate
the proportion of the variant and wt viruses by measuring peak
height (using an in-house measurement program). Following
propagation, we sequenced the entire viruses to verify that no
reversion or additional mutations occurred outside of the gene of
interest. The fitness of the variant viruses relative to the wt viruses
were calculated using the method described by Wu and colleagues
[42].
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